Pyrazinamide and Q203 Combination Therapy for Tuberculosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tuberculosis are lengthy, require multiple drugs, and are ineffective against multi-drug-resistant strains and latent infections, posing challenges in compliance and the rising threat of antibiotic resistance.
Innovation Solution
A combination therapy using pyrazinamide and Q203, a cytochrome bc1 inhibitor, which synergistically targets Mycobacterium tuberculosis, potentially shortening treatment duration and reducing the number of required drugs, while being effective against both active and latent forms, including multi-drug-resistant strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard tuberculosis treatment regimens are used, then bacterial burden is reduced and patients become non-infectious, but treatment duration extends to 6-24 months requiring intensive supervision
Solution Approach 1:
The patent combines pyrazinamide (a known anti-TB drug) with Q203 (a cytochrome bc1 inhibitor) to create a synergistic combination therapy. This merging of two different mechanisms of action achieves enhanced bactericidal activity that can potentially shorten treatment duration while maintaining effectiveness against M. tuberculosis
Solution Approach 2:
The invention changes the pharmacological parameters by introducing Q203 which targets cytochrome bc1 complex, a different metabolic pathway than traditional anti-TB drugs. This parameter change in mechanism of action creates new therapeutic possibilities for shortening treatment duration and improving compliance
2Reliability
If multiple drugs are administered to ensure effectiveness, then treatment coverage is comprehensive, but patient compliance and provider supervision become more difficult
Solution Approach 1:
By merging pyrazinamide and Q203 into a combination therapy, the patent aims to achieve comprehensive treatment coverage with a defined regimen that is easier to manage than current multi-drug protocols requiring 6-24 months of intensive supervision
3Reliability
If existing combination therapies are used, then some bacterial burden reduction is achieved, but treatment of multi-drug-resistant strains and latent infections remains ineffective
Solution Approach 1:
The patent introduces Q203 which targets cytochrome bc1 complex, representing a fundamental parameter change in mechanism of action compared to traditional anti-TB drugs. This new mechanism shows activity against MDR-TB and latent infections by attacking a different metabolic pathway that remains vulnerable even when other drug targets are resistant
Solution Approach 2:
The combination of pyrazinamide and Q203 demonstrates multi-functionality by showing effectiveness against multiple forms of tuberculosis including active disease, latent infections, and multi-drug-resistant strains, making it a versatile treatment option
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of pyrazinamide and Q203 demonstrates potent activity against Mycobacterium tuberculosis, offering a shorter treatment regimen, improved compliance, and effectiveness against drug-resistant strains, including latent infections, thereby addressing the limitations of existing tuberculosis treatments.
Implementation Method 1
Q203, or a pharmaceutically acceptable salt thereof, a cytochrome bc1 inhibitor
Data Source
Figure 1
AI summary
The present invention relates to novel combinations, which are useful in the treatment of tuberculosis.